VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.
This proof-of-concept data is significant because it addresses a key challenge in oncology: selectively targeting cancer cells while sparing healthy tissue. Traditional antibody-drug conjugates (ADCs) can cause off-target toxicity, limiting their therapeutic window. VERAXA's BiTAC-ADC platform uses a split-payload approach, where two inactive components are delivered separately and only combine in the tumor microenvironment, potentially reducing systemic side effects. The 3D spheroid data suggest the platform can penetrate solid tumors effectively, a crucial feature for treating breast cancer and other solid malignancies.
The company's pipeline includes both BiTAC-ADCs and BiTAC-TCEs (bispecific T cell engagers), giving VERAXA two complementary modalities. The BiTAC-TCE platform has previously shown promise in redirecting T cells to tumor cells. By combining these approaches, VERAXA aims to offer a broader toolkit for oncologists. The upcoming BIO International Convention provides a venue for potential licensing or collaboration deals, which could accelerate clinical development.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company's quality-by-design principles guide its development of next-generation antibody-based therapeutics. For the latest news and updates relating to VRXA, visit the company's newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All parties undertake no duty to update this information unless required by law. The full disclaimer is available at http://IBN.fm/Disclaimer.
